4//SEC Filing
EDELMAN JOSEPH 4
Accession 0001193125-25-246871
CIK 0002006986other
Filed
Oct 21, 8:00 PM ET
Accepted
Oct 22, 4:33 PM ET
Size
17.9 KB
Accession
0001193125-25-246871
Insider Transaction Report
Form 4
PERCEPTIVE ADVISORS LLC
Director10% Owner
Transactions
- Purchase
Tranche B Warrant ("Common Warrant" right to buy)
2025-10-20$0.18/sh+1,344,999$248,287→ 1,344,999 total(indirect: See footnote)Exercise: $1.71→ Common Stock or Pre-Funded Warrants (1,344,999 underlying) - Purchase
Pre-Funded Warrant (right to buy)
2025-10-20$1.60/sh+2,190,496$3,505,232→ 2,190,496 total(indirect: See footnote)Exercise: $0.00→ Common Stock (2,190,496 underlying) - Purchase
Tranche A Warrant ("Common Warrant" right to buy)
2025-10-20$0.18/sh+1,344,999$248,287→ 1,344,999 total(indirect: See footnote)Exercise: $1.71→ Common Stock or Pre-Funded Warrants (1,344,999 underlying) - Purchase
Tranche C Warrant ("Common Warrant" right to buy)
2025-10-20$0.18/sh+1,344,999$248,287→ 1,344,999 total(indirect: See footnote)Exercise: $1.71→ Common Stock or Pre-Funded Warrants (1,344,999 underlying)
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD
Director10% Owner
Transactions
- Purchase
Tranche B Warrant ("Common Warrant" right to buy)
2025-10-20$0.18/sh+1,344,999$248,287→ 1,344,999 total(indirect: See footnote)Exercise: $1.71→ Common Stock or Pre-Funded Warrants (1,344,999 underlying) - Purchase
Tranche C Warrant ("Common Warrant" right to buy)
2025-10-20$0.18/sh+1,344,999$248,287→ 1,344,999 total(indirect: See footnote)Exercise: $1.71→ Common Stock or Pre-Funded Warrants (1,344,999 underlying) - Purchase
Tranche A Warrant ("Common Warrant" right to buy)
2025-10-20$0.18/sh+1,344,999$248,287→ 1,344,999 total(indirect: See footnote)Exercise: $1.71→ Common Stock or Pre-Funded Warrants (1,344,999 underlying) - Purchase
Pre-Funded Warrant (right to buy)
2025-10-20$1.60/sh+2,190,496$3,505,232→ 2,190,496 total(indirect: See footnote)Exercise: $0.00→ Common Stock (2,190,496 underlying)
EDELMAN JOSEPH
Director10% Owner
Transactions
- Purchase
Tranche A Warrant ("Common Warrant" right to buy)
2025-10-20$0.18/sh+1,344,999$248,287→ 1,344,999 total(indirect: See footnote)Exercise: $1.71→ Common Stock or Pre-Funded Warrants (1,344,999 underlying) - Purchase
Tranche B Warrant ("Common Warrant" right to buy)
2025-10-20$0.18/sh+1,344,999$248,287→ 1,344,999 total(indirect: See footnote)Exercise: $1.71→ Common Stock or Pre-Funded Warrants (1,344,999 underlying) - Purchase
Pre-Funded Warrant (right to buy)
2025-10-20$1.60/sh+2,190,496$3,505,232→ 2,190,496 total(indirect: See footnote)Exercise: $0.00→ Common Stock (2,190,496 underlying) - Purchase
Tranche C Warrant ("Common Warrant" right to buy)
2025-10-20$0.18/sh+1,344,999$248,287→ 1,344,999 total(indirect: See footnote)Exercise: $1.71→ Common Stock or Pre-Funded Warrants (1,344,999 underlying)
Footnotes (5)
- [F1]The common warrants are immediately exercisable, subject to the Beneficial Ownership Limitation (as defined below), and will expire on the fifth anniversary of their issuance. Pursuant to the terms of the common warrants, the common warrant cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise (the "Beneficial Ownership Limitation").
- [F2]Represents the purchase price for each common warrant purchased by the Reporting Person in the Issuer's registered public offering that closed on October 20, 2025.
- [F3]The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
- [F4]The pre-funded warrants are immediately exercisable, subject to the Beneficial Ownership Limitation, and will expire on the date they are exercised in full.
- [F5]Represents the purchase price for each pre-funded warrant purchased by the Reporting Person in the Issuer's registered public offering that closed on October 20, 2025.
Documents
Issuer
Adagio Medical Holdings, Inc.
CIK 0002006986
Entity typeother
Related Parties
1- filerCIK 0001164426
Filing Metadata
- Form type
- 4
- Filed
- Oct 21, 8:00 PM ET
- Accepted
- Oct 22, 4:33 PM ET
- Size
- 17.9 KB